These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36145630)

  • 21. Current trends in the real-life use of dalbavancin: report of a study panel.
    Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
    Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
    Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals.
    Bai F; Mazzitelli M; Silvola S; Raumer F; Restelli U; Croce D; Marchetti G; Cattelan AM
    JAC Antimicrob Resist; 2023 Apr; 5(2):dlad044. PubMed ID: 37090914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
    Simonetti O; Rizzetto G; Molinelli E; Cirioni O; Offidani A
    Ther Clin Risk Manag; 2021; 17():223-232. PubMed ID: 33790563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
    Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
    Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.
    Van Matre ET; Teitelbaum I; Kiser TH
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections.
    Wang Y; Wang J; Wang R; Li Y; Cai Y
    J Glob Antimicrob Resist; 2021 Mar; 24():72-80. PubMed ID: 33279683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the Use of Dalbavancin for Off-Label Indications.
    Taylor K; Williamson J; Luther V; Stone T; Johnson J; Gruss Z; Russ-Friedman C; Ohl C; Beardsley J
    Infect Dis Rep; 2022 Apr; 14(2):266-272. PubMed ID: 35447884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
    Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
    Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dalbavancin Use in the Emergency Department Setting.
    Patel M; Smalley S; Dubrovskaya Y; Siegfried J; Caspers C; Pham V; Press RA; Papadopoulos J
    Ann Pharmacother; 2019 Nov; 53(11):1093-1101. PubMed ID: 31155916
    [No Abstract]   [Full Text] [Related]  

  • 34. Dalbavancin: Quantification in human plasma and urine by a new improved high performance liquid chromatography-tandem mass spectrometry method.
    Alebic-Kolbah T; Demers R; Cojocaru L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(25):2632-41. PubMed ID: 21831727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
    Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility.
    Almangour TA; Perry GK; Terriff CM; Alhifany AA; Kaye KS
    Diagn Microbiol Infect Dis; 2019 Mar; 93(3):213-218. PubMed ID: 30396697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections.
    Rappo U; Gonzalez PL; Puttagunta S; Akinapelli K; Keyloun K; Gillard P; Liu Y; Dunne MW
    J Glob Antimicrob Resist; 2019 Jun; 17():60-65. PubMed ID: 30797084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections.
    Roecker AM; Pope SD
    Expert Opin Pharmacother; 2008 Jul; 9(10):1745-54. PubMed ID: 18570607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.